New drug BGM-2121 enters first human tests for advanced cancers
NCT ID NCT07346846
First seen Feb 01, 2026 · Last updated Apr 30, 2026 · Updated 10 times
Summary
This early-phase study tests a new drug called BGM-2121 in about 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. This is a first-in-human trial, so it focuses on side effects and how the body handles the drug, not on curing the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cheng Kung University Hospital
NOT_YET_RECRUITINGTainan, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Taiwan University Hospital
NOT_YET_RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.